Inactive Instrument

Pharmacyclics, Inc. Share Price

Stocks

End-of-day quote Nasdaq
- ^USD	-

06/05/15	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
29/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE

06/05/15	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
29/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE
21/04/15	Mylan NV : Generic drugmaker Teva makes $40 billion offer for rival Mylan	RE
21/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan offer as soon as this week	RE
08/04/15	Actavis : Generic drugmaker Mylan offers $29 billion for Perrigo	RE
05/03/15	AbbVie : CEO defends Pharmacyclics deal to sceptical investors	RE
05/03/15	Wall Street closes up slightly ahead of jobs report	RE
05/03/15	AbbVie : CEO says new form of Humira could thwart generics	RE
05/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
05/03/15	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
05/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
02/06/14	Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels	RE

07/01/16	Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma	PU
07/01/16	Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers	PU
07/01/16	Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent	PU
07/01/16	Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia	PU
07/01/16	Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe	PU

05/03/15	Wall Street se reprend un peu dans un climat d'attente
05/03/15	DJ Industrial : Wall Street se reprend un peu dans un climat d'attente
05/03/15	AbbVie : Début d'année en fanfare pour les fusions dans la pharmacie
05/03/15	Début d'année en fanfare pour les fusions dans la pharmacie
05/03/15	AbbVie : Wall Street quasiment stable après les chiffres du chômage

Manager	Title	Age	Since
Scott Reents PRN	Corporate Officer/Principal	59	-
Dana Lee PRN	Corporate Officer/Principal	62	31/01/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	-2.23%	-6.75%	-4.29%	+11.66%	48.01B
REVOLUTION MEDICINES, INC.	+2.27%	+0.49%	+413.56%	+539.64%	44.44B
IQVIA HOLDINGS INC.	-1.62%	-2.89%	+35.11%	+18.99%	42.67B
BEONE MEDICINES AG	-0.34%	-2.88%	+0.06%	+67.92%	39.96B
CELLTRION, INC.	-1.72%	-2.61%	+13.09%	+42.33%	32.75B
ASCENDIS PHARMA A/S	-0.88%	+0.45%	-	-	17.74B
MEDPACE HOLDINGS, INC.	-1.91%	-1.53%	+20.25%	+109.03%	16.49B
EUROFINS SCIENTIFIC SE	+0.08%	-2.06%	+11.44%	+31.56%	14.38B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.21%	-3.78%	+78.39%	+40.61%	13.4B
Average	-0.84%	-0.48%	+70.95%	+107.72%	29.98B
Weighted average by Cap.	-0.77%	-1.05%	+85.88%	+127.91%